Author

Khisimuzi E. Mdluli

TB Alliance

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:mouse· 3 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

Alessia Tagliavini· 3 shared Anna M. UptoniD· 3 shared David J. Hermann· 3 shared Debra Flood· 3 shared Denise FedericoiD· 3 shared Marco Pergher· 3 shared Sylvie SordelloiD· 3 shared Xavier BoulenciD· 3 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

Alessia Tagliavini

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Next Generation TB Drug Combinations from the Pan-TB Consortium: Combination Efficacy and Contributions of Individual Agents, Evaluated in a BALB/c Mouse TB Model

Sylvie Sordello, Alain Le Coupanec, Zoï Vahlas, Chiara Roversi, ROBERTO VISENTIN, Xavier Boulenc, Denise Federico, Simone Zannoni, Simone Modolo, Augusto Celon, Roberto Petterlini, Cécile Pascal, Fanny Deglave, Alessia Tagliavini, Marco Pergher, , Anna M. Upton

The paper evaluates next-generation TB drug combinations in a mouse model, showing some regimens cure 90% of mice in under 2 months with faster sterilizing efficacy than existing treatments.

bioRxiv · Jun 23, 2026 · PreprintPharmacology & Toxicology

Nonclinical pharmacokinetics and relative efficacy of the first 25 novel tuberculosis drug combinations from the PAN-TB consortium: Use of the BALB/c relapsing mouse model and combination pharmacokinetics within a modeling-based framework

Sylvie Sordello, Alessia Tagliavini, Xavier Boulenc, Laure Brock, Simone Zannoni, Chiara Roversi, ROBERTO VISENTIN, Darren Metcalf, Denise Federico, Simone Modolo, Giulia Calusi, Roberto Petterlini, Guillaume R. Golovkine, Cécile Pascal, Emilie Huc‐Claustre, , Anna M. Upton

The paper evaluates 25 tuberculosis drug combinations in a mouse model, finding 15 combinations with T90 <5 months and three top combinations curing 90% of mice in <3 months.

bioRxiv · May 7, 2026 · PreprintMicrobiology

A modeling-based framework to evaluate forgiveness of TB drug combinations in a BALB/c relapsing mouse model.

Sylvie Sordello, Laure Brock, Alessia Tagliavini, Denise Federico, Xavier Boulenc, Marco Pergher, Emilie Huc‐Claustre, Darren Metcalf, Nicholas D. Walter, Gregory T. Robertson, James Clary, Alexander K. Berg, Khisimuzi E. Mdluli, David J. Hermann, Debra Flood, Anna M. Upton

This study evaluates the forgiveness of TB drug combinations using a mouse model, finding BPaMZ is more forgiving of missed doses than RHZE/RH.

bioRxiv · Aug 7, 2025 · PreprintPharmacology & Toxicology

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

Lourdes Encinas, Si‐Yang Li, Joaquín Rullás, Rokeya Tasneen, Sandeep K. Tyagi, Heena Soni, Adolfo García-Pérez, Jin Lee, Rubén González del Río, Jaime de Mercado, Verónica Sousa, Izidor Sosič, Stanislav Gobec, Alfonso Mendoza-Losana, Paul J. Converse, , Eric L. Nuermberger

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

Antimicrobial Agents and Chemotherapy · Sep 30, 2024Peer-reviewedPharmacology & Toxicology